RapidARC is a brand name for a radiation machine. You can read what the manufacturer says here:www.varian.com/us/oncology/treatments/treatment_techniques/rapidarc/
It is hard to tell if this is a treatment breakthrough or just product puffery.
Here is an abstreact from a medical journal
RapidArc volumetric modulated therapy planning for prostate cancer patients
Authors: Flemming Kjaeligr-Kristoffersen a; Lars Ohlhues a; Joakim Medin a; Stine Korreman a
Affiliation: a Department of Radiation Oncology, Rigshospitalet, C
openhagen University Hospital, Denmark
Publication Frequency: 8 issues per year
Published in: journal Acta Oncologica, Volume 48, Issue 2 February 2009 , pages 227 - 232
First Published: February 2009
Purpose. Recently, Varian Medical Systems have announced the introduction of a new treatment technique, RapidArc, in which dose is delivered over a single gantry rotation with dynamically variable MLC positions, dose rate and gantry speed. At Rigshospitalet, the RapidArc technique was brought into clinical practice in May 2008 for treatment of prostate cancer patients. We report here our experiences with performing treatment planning using the Eclipse RapidArc optimization software for this patient group. Material and methods. A stand-alone installation of Eclipse 8.5 with RapidArc optimization capability was performed at Rigshospitalet. Patient data for 8 prostate cancer patients were imported, most of whom were previously treated at Rigshospitalet using IMRT. Three of the patients were treated at Rigshospitalet using the RapidArc technique. Treatment plans were optimized using objectives as given by standard guidelines for clinical treatment planning. RapidArc plans were compared to the IMRT plans by which the patients were actually treated or in the three cases treated with the RapidArc technique to IMRT plans achieved using standard guidelines. Comparison was done with respect to target coverage, doses to rectum and bladder, over-all maximum dose and number of monitor units. Results. Overall, the RapidArc treatment plans gave better or equal sparing of the organs at risk than the IMRT treatment plans. The number of monitor units was lower in most cases, by up to approximately 75%. However, the target dose homogeneity was not as high as for IMRT. The low-dose bath was larger than for IMRT. Conclusion. RapidArc optimization is very promising, especially regarding the potential of reducing the number of monitor units, while providing good sparing of organs at risk. Some improvement is still warranted with respect to achieving high target dose homogeneity.
Age at diagnosis 66, PSA 5.5
Biopsy 12/08 12 cores, 8 positive
CAT scan, Bone scan 1/09 both negative.
Robotic surgery 03/03/09 Catheter Out 03/08/09
Pathology: Lymph nodes & Seminal vesicles negative
Margins positive, Capsular penetration extensive Gleason 4+3=7
6 weeks: 1 pad/day, 1 pad/night -- mostly dry at night.
10 weeks: no pad at night -- slight leakage day/1 pad.
3 mo. PSA 0.0 - now light pads
Post Edited (geezer99) : 8/26/2009 7:59:06 PM (GMT-6)